Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 152

1.

Dietary Interventions for Gout and Effect on Cardiovascular Risk Factors: A Systematic Review.

Vedder D, Walrabenstein W, Heslinga M, de Vries R, Nurmohamed M, van Schaardenburg D, Gerritsen M.

Nutrients. 2019 Dec 4;11(12). pii: E2955. doi: 10.3390/nu11122955. Review.

2.

The effect of methotrexate on tumour necrosis factor concentrations in etanercept-treated rheumatoid arthritis patients.

Berkhout LC, l'Ami MJ, Krieckaert CLM, Vogelzang EH, Kos D, Nurmohamed MT, Wolbink GJ, Rispens T.

Rheumatology (Oxford). 2019 Nov 6. pii: kez513. doi: 10.1093/rheumatology/kez513. [Epub ahead of print]

PMID:
31691828
3.

Do DMARDs and biologic agents protect from cardiovascular disease in patients with inflammatory arthropathies?

Atzeni F, Svenungsson E, Nurmohamed MT.

Autoimmun Rev. 2019 Dec;18(12):102401. doi: 10.1016/j.autrev.2019.102401. Epub 2019 Oct 23. Review. No abstract available.

PMID:
31655302
4.

Sustained remission with methotrexate monotherapy after 22-week induction treatment with TNF-alpha inhibitor and methotrexate in early psoriatic arthritis: an open-label extension of a randomized placebo-controlled trial.

de Jong HMY, van Mens LJJ, Nurmohamed MT, Kok MR, van Kuijk AWR, Baeten DLP, van de Sande MGH.

Arthritis Res Ther. 2019 Sep 14;21(1):208. doi: 10.1186/s13075-019-1998-4.

5.

The effect of certolizumab drug concentration and anti-drug antibodies on TNF neutralisation.

Berkhout LC, Vogelzang EH, Hart MM, Loeff FC, Dijk L, Derksen NIL, Wieringa R, van Leeuwen WA, Krieckaert CLM, de Vries A, Nurmohamed MT, Wolbink GJ, Rispens T.

Clin Exp Rheumatol. 2019 Aug 30. [Epub ahead of print]

PMID:
31498069
6.

Response to: "Influence of changes in cholesterol levels and disease activity on the 10-year cardiovascular risk estimated with different algorithms in rheumatoid arthritis patients" by Fornaro et al.

Agca R, Heslinga SC, Rollefstad S, Heslinga S, Södergren A, Semb AG, Kitas GD, Sattar N, Nurmohamed MT; EULAR task force “EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update”.

Ann Rheum Dis. 2019 Aug 14. pii: annrheumdis-2019-215748. doi: 10.1136/annrheumdis-2019-215748. [Epub ahead of print] No abstract available.

PMID:
31413003
7.

Methotrexate for Prevention of Cardiovascular Events.

van Vollenhoven RF, Nurmohamed M.

N Engl J Med. 2019 Jun 6;380(23):2276-2277. doi: 10.1056/NEJMc1905061. No abstract available.

PMID:
31167066
8.

Cardiovascular Event Risk in Rheumatoid Arthritis Compared with Type 2 Diabetes: A 15-year Longitudinal Study.

Agca R, Hopman LHGA, Laan KJC, van Halm VP, Peters MJL, Smulders YM, Dekker JM, Nijpels G, Stehouwer CDA, Voskuyl AE, Boers M, Lems WF, Nurmohamed MT.

J Rheumatol. 2019 May 15. pii: jrheum.180726. doi: 10.3899/jrheum.180726. [Epub ahead of print]

PMID:
31092721
9.

Response to: 'Tapering without relapse in rheumatoid arthritis patients with high TNF blocker concentrations: data from the STRASS study' by Marotte et al.

l'Ami MJ, Krieckaert CL, Nurmohamed MT, van Vollenhoven RF, Rispens T, Boers M, Wolbink GJ.

Ann Rheum Dis. 2019 May 9. pii: annrheumdis-2019-215609. doi: 10.1136/annrheumdis-2019-215609. [Epub ahead of print] No abstract available.

PMID:
31072816
10.

Can personalized use of NSAIDs be a reality in the clinic?

Nurmohamed MT.

Nat Rev Rheumatol. 2019 Jul;15(7):387-388. doi: 10.1038/s41584-019-0225-7. No abstract available.

PMID:
31040441
11.

Long-term safety and effectiveness of tocilizumab in patients with rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: an open-label study close to clinical practice.

Bykerk VP, Östör AJK, Alvaro-Gracia J, Pavelka K, Román Ivorra JA, Nurmohamed MT, Luder Y, Sidiropoulos PNM, Devenport J, Sibilia J.

Clin Rheumatol. 2019 Sep;38(9):2411-2421. doi: 10.1007/s10067-019-04535-z. Epub 2019 Apr 26.

PMID:
31028551
12.

Antidrug antibody detection for adalimumab depends on the type of assay used: an experimental approach to help clinicians interpret diagnostic data.

Ruwaard J, Marsman AF, Nurmohamed MT, van der Horst-Bruinsma IE, Te Velthuis H, Bloem K, de Vries A, Rispens T, Wolbink G.

Clin Exp Rheumatol. 2019 Sep-Oct;37(5):756-761. Epub 2019 Mar 18.

13.

Achieving remission in psoriatic arthritis by early initiation of TNF inhibition: a double-blind, randomised, placebo-controlled trial of golimumab plus methotrexate versus placebo plus methotrexate.

van Mens LJJ, de Jong HM, Fluri I, Nurmohamed MT, van de Sande MGH, Kok M, van Kuijk AWR, Baeten D.

Ann Rheum Dis. 2019 May;78(5):610-616. doi: 10.1136/annrheumdis-2018-214746. Epub 2019 Feb 26.

14.

Change in cardiovascular risk after initiation of anti-rheumatic treatment in early rheumatoid arthritis.

Turk SA, Heslinga M, Twisk J, van der Lugt V, Lems WF, van Schaardenburg D, Nurmohamed MT.

Clin Exp Rheumatol. 2019 May-Jun;37(3):513. Epub 2019 Feb 15. No abstract available.

15.

Microvascular heart involvement in systemic autoimmune diseases: The purinergic pathway and therapeutic insights from the biology of the diseases.

De Lorenzis E, Gremese E, Bosello S, Nurmohamed MT, Sinagra G, Ferraccioli G.

Autoimmun Rev. 2019 Apr;18(4):317-324. doi: 10.1016/j.autrev.2019.02.002. Epub 2019 Feb 7. Review. No abstract available.

PMID:
30743079
16.

Dynamics of circulating TNF during adalimumab treatment using a drug-tolerant TNF assay.

Berkhout LC, l'Ami MJ, Ruwaard J, Hart MH, Heer PO, Bloem K, Nurmohamed MT, van Vollenhoven RF, Boers M, Alvarez DF, Smith CH, Wolbink GJ, Rispens T.

Sci Transl Med. 2019 Jan 30;11(477). pii: eaat3356. doi: 10.1126/scitranslmed.aat3356.

PMID:
30700574
17.

Long-Term Treatment With TNF-Alpha Inhibitors Improves Bone Mineral Density But Not Vertebral Fracture Progression in Ankylosing Spondylitis.

Beek KJ, Rusman T, van der Weijden MAC, Lems WF, van Denderen JC, Konsta M, Visman I, Nurmohamed MT, van der Horst-Bruinsma IE.

J Bone Miner Res. 2019 Jun;34(6):1041-1048. doi: 10.1002/jbmr.3684. Epub 2019 Mar 25.

PMID:
30690799
18.

Reduced Occurrence Rate of Acute Anterior Uveitis in Ankylosing Spondylitis Treated with Golimumab - The GO-EASY Study.

van Bentum RE, Heslinga SC, Nurmohamed MT, Gerards AH, Griep EN, Koehorst CBJM, Kok MR, Schilder AM, Verhoef M, van der Horst-Bruinsma IE.

J Rheumatol. 2019 Feb;46(2):153-159. doi: 10.3899/jrheum.180312. Epub 2018 Nov 1.

19.

Multicentric reticulohistiocytosis: a case report.

Farokhi A, van Vugt RM, Hoekzema R, Nurmohamed MT.

BMC Res Notes. 2018 Sep 4;11(1):647. doi: 10.1186/s13104-018-3753-3.

20.

Editorial: Comorbidity Burden in Rheumatic Diseases.

Nikiphorou E, Nurmohamed MT, Szekanecz Z.

Front Med (Lausanne). 2018 Jul 3;5:197. doi: 10.3389/fmed.2018.00197. eCollection 2018. No abstract available.

Supplemental Content

Loading ...
Support Center